Katsumi Miyauchi Selected Research

Atherosclerosis

1/2020	Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor α modular (SPPARMα), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury.
7/2019	The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials.
1/2015	Elevated Circulating Levels of Inflammatory Markers in Patients with Acute Coronary Syndrome.
2/2014	Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke.
1/2013	Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study.
9/2009	Morning home blood pressure may be a significant marker of nephropathy in Japanese patients with type 2 diabetes: ADVANCED-J study 1.
11/2006	Insulin and nateglinide reduce monocyte adhesion to endothelial cells in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.
6/2004	Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katsumi Miyauchi Research Topics

Disease

84	Coronary Artery Disease (Coronary Atherosclerosis) 10/2022 - 03/2002
65	Acute Coronary Syndrome 01/2022 - 05/2004
42	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2004
22	Myocardial Infarction 05/2022 - 01/2007
16	Atrial Fibrillation 09/2022 - 01/2018
14	Inflammation (Inflammations) 04/2020 - 06/2004
13	Heart Failure 09/2022 - 10/2008
11	Hemorrhage 09/2022 - 08/2015
11	Chronic Renal Insufficiency 01/2022 - 09/2011
11	Diabetes Mellitus 01/2018 - 10/2006
9	Coronary Disease (Coronary Heart Disease) 09/2022 - 01/2008
9	Hypertension (High Blood Pressure) 05/2022 - 02/2008
9	Thrombosis (Thrombus) 05/2022 - 08/2010
9	Stroke (Strokes) 11/2021 - 03/2009
9	Death (Near-Death Experience) 05/2021 - 01/2006
9	Atherosclerotic Plaque (Atheroma) 05/2020 - 09/2010
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2012 - 12/2006
8	Stable Angina 10/2021 - 11/2012
8	Atherosclerosis 01/2020 - 06/2004
7	Hypercholesterolemia 01/2019 - 04/2008
6	Neoplasms (Cancer) 11/2022 - 01/2007
6	Hyperplasia 10/2010 - 03/2004
5	Pathologic Constriction (Stenosis) 08/2018 - 03/2004
5	Dyslipidemias (Dyslipidemia) 11/2016 - 01/2011
4	Hyperglycemia 01/2019 - 11/2006
4	Type 2 Diabetes Mellitus (MODY) 01/2019 - 10/2006
3	Unstable Angina 11/2021 - 01/2007
3	Peripheral Arterial Disease 11/2021 - 01/2011
3	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2019 - 09/2009
2	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 08/2017
2	Pain (Aches) 01/2022 - 09/2007
2	Embolism (Embolus) 11/2021 - 01/2019
2	Intermittent Claudication 11/2021 - 07/2021
2	Left Ventricular Dysfunction 01/2019 - 06/2012
2	Coronary Stenosis (Coronary Artery Stenosis) 01/2019 - 11/2017
2	Sleep Apnea Syndromes (Sleep Apnea) 10/2018 - 08/2018
2	Malnutrition (Nutritional Deficiencies) 11/2017 - 06/2017
2	Vascular Diseases (Vascular Disease) 09/2017 - 01/2011
2	Critical Illness (Critically Ill) 06/2017 - 06/2015

Drug/Important Bio-Agent (IBA)

43	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 06/2004
23	LipidsIBA 10/2022 - 08/2004
22	omega-Chloroacetophenone (Mace)IBA 01/2022 - 09/2010
21	oxidized low density lipoproteinIBA 07/2021 - 03/2004
16	LDL CholesterolIBA 10/2022 - 02/2008
13	pitavastatin (itavastatin)FDA Link 10/2022 - 06/2004
13	C-Reactive ProteinIBA 11/2021 - 09/2009
11	RivaroxabanIBA 09/2022 - 08/2018
11	Atorvastatin (Lipitor)FDA Link 01/2019 - 05/2004
7	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 11/2021 - 01/2006
7	Biomarkers (Surrogate Marker)IBA 01/2019 - 05/2011
6	AnticoagulantsIBA 01/2022 - 01/2018
6	Lipoprotein(a)IBA 01/2022 - 02/2016
6	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2020 - 02/2014
6	Triglycerides (Triacylglycerol)IBA 06/2019 - 09/2009
6	Amlodipine (Norvasc)FDA LinkGeneric 10/2012 - 10/2006
5	HDL CholesterolIBA 01/2022 - 09/2010
5	CholesterolIBA 06/2019 - 03/2009
5	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2019 - 09/2009
5	Hemoglobins (Hemoglobin)IBA 11/2017 - 03/2011
5	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2015 - 10/2006
4	Rosuvastatin Calcium (Crestor)FDA Link 01/2019 - 01/2009
4	lysophosphatidic acidIBA 01/2018 - 01/2012
4	AlbuminsIBA 09/2017 - 09/2009
4	azelnidipineIBA 01/2015 - 10/2009
4	Angiotensin Receptor AntagonistsIBA 01/2012 - 09/2009
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2021 - 01/2006
3	LDL Receptors (LDL Receptor)IBA 05/2020 - 01/2016
3	1,5-anhydroglucitolIBA 01/2019 - 10/2016
3	Eicosapentaenoic AcidIBA 01/2018 - 01/2016
3	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2018 - 08/2015
3	Arachidonic Acid (Vitamin F)IBA 01/2018 - 01/2016
3	Docosahexaenoic AcidsIBA 01/2018 - 01/2016
3	8,11,14-Eicosatrienoic Acid (Dihomo-gamma-Linolenic Acid)IBA 01/2018 - 08/2017
3	Glucose (Dextrose)FDA LinkGeneric 11/2017 - 02/2014
3	Serum AlbuminIBA 11/2017 - 08/2017
3	pro-brain natriuretic peptide (1-76)IBA 08/2017 - 05/2011
3	Antihypertensive Agents (Antihypertensives)IBA 01/2015 - 10/2006
3	LDL Lipoproteins (beta Lipoproteins)IBA 07/2011 - 02/2008
2	CreatinineIBA 09/2022 - 09/2009
2	Pharmaceutical PreparationsIBA 05/2022 - 01/2012
2	DiureticsIBA 04/2022 - 05/2017
2	Warfarin (Coumadin)FDA LinkGeneric 01/2022 - 12/2016
2	Insulin (Novolin)FDA Link 01/2022 - 11/2006
2	Everolimus FDA Link 11/2021 - 10/2015
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2020 - 10/2010
2	SteroidsIBA 01/2019 - 11/2017
2	alirocumabIBA 01/2019 - 01/2018
2	CalciumIBA 01/2019 - 08/2015
2	Choline (Choline Chloride)IBA 01/2018 - 11/2012
2	LysophospholipidsIBA 01/2017 - 02/2015

Therapy/Procedure

55	Percutaneous Coronary Intervention 11/2022 - 12/2006
55	Therapeutics 10/2022 - 01/2007
16	Stents 11/2021 - 03/2004
14	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2019 - 02/2008
9	Drug-Eluting Stents 11/2021 - 08/2010
4	Secondary Prevention 06/2016 - 02/2010
3	Renal Dialysis (Hemodialysis) 01/2022 - 11/2016
3	Glycemic Control 11/2017 - 10/2006
2	Cardiac Rehabilitation 12/2018 - 01/2015
2	Catheters 07/2018 - 01/2018